))
How Innovation Can Broaden Access and Propel the CGT Industry Forward
Manage episode 441419039 series 2994360
Content provided by [email protected] and TTP plc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by [email protected] and TTP plc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of development, to ensure that these therapies reach the patients who need them.
Guests:
- Emma Chan, Director of Technical Development at Orchard Therapeutics
- Matt Hewitt, Chief Technical Officer at the Manufacturing Business Division at Charles River Laboratories
26 episodes
Share
